key: cord-0689468-iaoj3onp
authors: Lazzeri, Chiara; Bonizzoli, Manuela; Batacchi, Stefano; Cianchi, Giovanni; Franci, Andrea; Socci, Filippo; Peris, Adriano
title: PERSISTENT RIGHT VENTRICLE DILATATION IN SARS-COV2-related ACUTE RESPIRATORY DISTRESS SYNDROME ON EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT
date: 2021-08-21
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.08.028
sha: d793a541a7a86500126992b5f9461f5493ec3762
doc_id: 689468
cord_uid: iaoj3onp

OBJECTIVE(S): Design; Setting; Participants; Interventions; Measurements & Main Results; Conclusions. OBJECTIVES: Veno-venous extracorporeal membrane oxygenation (ECMO) support may be considered in experienced centers for patients with Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV2 infection (COVID) refractory to conventional treatment. In ECMO patients, echocardiography has emerged as a clinical tool for implantation and clinical management, but to date, little data are available on COVID-related ARDS patients requiring ECMO. We assessed the incidence of RV dilatation and dysfunction (RvDys) in patients with COVID-related ARDS patients requiring ECMO. DESIGN: single-center investigation. SETTING: intensive care unit (ICU). PARTICIPANTS: 35 patients with COVID-related ARDS patients requiring ECMO, consectively admitted to our ICU (1 st March 2020 to 28(th) February 2021). INTERVENTIONS: serial echocardiographic examinations. RV Dys was defined as RVEDA/LVEDA > 0.6 and TAPSE < 15 mm. MEASUREMENTS AND MAIN RESULTS: The incidence of RvDys was 15/35 (42%). RVdys patients underwent ECMO support after a longer period of mechanical ventilation (p=0.006) and exhibited a higher mortality rate (p=0.024) than those without RVDys. In non survivors, RV Dys was observed in all patients (n.9), who died for unfavourable progression of COVID-related ARDS. In survivors, weaned from ECMO, a significant reduction in systolic pulmonary arterial pressures was detectable. CONCLUSIONS: According to our data, in COVID-related ARDS requiring ECMO support, RVDys is common, associated with increased ICU mortality. Overall our data underscore the clinical role of echocardiography in COVID-related ARDS supported by VV ECMO, since serial echocardiographic assessments (especially focused on RV changes) are able to reflect pulmonary COVID disease severity.

The clinical course of Coronavirus -19 disease (COVID) is known to evolve, in up to 15% of infected patients, into a severe form of acute respiratory syndrome (ARDS) requiring mechanical ventilation and admission to intensive care unit (ICU). Treatment for these patients comprises conventional therapies established for ARDS, including lung protective ventilatory strategies, neuromusclar blockade and prone positioning [1, 2] . For those patients who exhibit progression of respiratory failure despite conventional treatment, veno-venous extracorporeal membrane oxygenation (ECMO) support may be considered in experienced centers [3] [4] [5] [6] [7] [8] [9] [10] .

In COVID patients with respiratory failure, right ventricular (RV) dysfunction is a common finding and associated with worse outcome [11] [12] [13] [14] [15] [16] , underscoring the clinical role of echocardiography especially in critically-ill COVID patients.

Also in patients on ECMO support, echocardiography has emerged as a clinical tool for implantation and clinical management. To date, little data are available on echocardiographic findings in COVID-related ARDS patients requiring ECMO.

We performed serial echocardiographic examinations in 35 patients with COVID-related ARDS patients requiring ECMO, consectively admitted to our ICU (which is an ECMO referral center). The objective was to the incidence of RV dilatation and dysfunction (RVDys) before ECMO implantation, after its removal and at discharge (in survivors) and on the day of death (in non-survivors).

In our case series study, we enrolled all patients with COVID-related ARDS refractory to conventional treatment submitted to VV ECMO and consecutively admitted to our ICU (which is an ECMO referral center, Azienda Ospedaliero-Universitaria Careggi) 1 st March 2020 to 28 th February 2021. The study protocol was approved by our Ethical Committee (n.17024, approved on March 31 th 2020) (-Florence COVID ICU Registry‖ ).

The written inform consent for each patient was waived for emerging infectious disease.

Patients'relatives were informed every day by phone on the clinical conditions of their kin. The need for ECMO support was communicated by phone before implantation to the patient's relatives.

On ICU admission we measured: troponin (pg/ml), N-terminal-pro brain natriuretic peptide (NT-BNP, pg/ml), C-reactive protein (CRP, mg/dl) creatinine (mg/dl), lactose dehydrogenase (LDH, UI/L), D-dimer (ng/ml), and interleukin 6 (IL-6, pg/ml).

According to our protocol [13, 14, 17] , an echocardiographic exam was performed before and during ECMO implantation, the first 24 hours, during the ICU when clinically indicated, and at discharge. Overall 321 exams were performed in our series, (per each patient median 8, range 5-15).

Among these 321 exams, 56 (53%) were both transesophageal and transthoracic examinations because of ECMO implantation (n. 35), suspicion for endocarditis (n. 7), and after ECMO removal (n. 14). In those patients submitted to pronation, echocardiograms were performed within 2 hours since returning from the prone to the supine position. We analyzed 87 exams, that is those performed before and during ECMO implantation, the first 24 hours (to assess RV Dys incidence and whether it is potentially reversible), after ECMO removal , at discharge (in survivors) and in the day of death in non-survivors. We hypothesized that echocardiographic assessments in these two subgroups (survivors and nonsurvivors) could reflect the complex spectrum of pulmonary disease severity in COVID infection. 2

All ultrasound cardiac procedures were performed using the necessary protective equipment for professionals. Dedicated machines were used in the COVID ICU and transducers are wrapped in single-use plastic covers [13, 14] .

The right ventricle size was assessed by the RV end-diastolic area (EDA) and the ratio between EDAs of the right and left ventricles was calculated (RVEDA/LVEDA). Systolic pulmonary artery pressure (sPAP) was obtained using the simplified Bernouilli's equation: 4 • (Vmax tricuspid regurgitation) 2 + central venous pressure (CVP). Each measure was performed three times, and the mean value was recorded. Tricuspid annular plane Excursion (TAPSE) was also measured, as the difference of displacement during diastole and systole, to assess RV function. The E/e1 ratio was also calculated as the ratio between E wave velocity and e' wave, early diastolic mitral annular velocity.

RV dilatation and dysfunction (RVDys) was defined as RVEDA/LVEDA > 0.6 and TAPSE < 15 mm.

We considered VV ECMO in COVID when respiratory failure persisted despite optimum management including controlled ventilation with tidal volume 6ml/kg, plateau pressure <30cm H2O, use of neuromuscular blockers, high-positive end-expiratory pressure (PEEP), and repeated prone positioning sessions [2, [6] [7] [8] [9] .

All patients were encouraged to mobilize early [17] . Primary outcome was death in the ICU.

Data have been stored in a dedicated data-base and analyzed with SPSS for Windows 20.0 (SPSS Inc., Chicago, IL). P value less than 0.05 was considered statistically significant. Categorical variables are reported as frequencies and percentages; continuous variables are reported as mean ± standard deviation (SD) or median (range), as needed. Comparisons between the groups were performed using Chi square for categorical data, and Student's t test and Kruskal-Wallis test for continuous data. 3

Our study population comprised of 35 consecutive patients with severe respiratory failure due to COVID infection, refractory to conventional treatment and requiring VV ECMO support.

Our series is constituted mainly by males (80%) and obese patients (BMI > 30, 71%). The majority of our patients came from peripheral hospitals (69%). The most common risk factors were hypertension and diabetes mellitus (34% and 31%, respectively). Inhaled nitric oxide was used in 8 patients (8/35, 23%) with no improvement in oxygenation. hours since removal) and at discharge. A progressive reduction in systolic pulmonary arterial pressure was observed associated with a reduction in E/e1.

The main findings of our single-center investigations, performed in consecutive patients with COVID-related ARDS refractory to conventional treatment treated with ECMO support [2, [6] [7] [8] [9] 18] , are as follows: a) RV dilatation and dysfunction is a common finding, being detectable in the 42% of the entire population and potentially reversible (about one third showed normalization of RV chamber within 24 hours after ECMO start); b) RV Dysf is associated with a longer mechanical ventilation before ECMO implantation and with an higher ICU mortality rate; c) in nonsurvivors RV Dys was detectable in those who died for progressive refractory COVID-related respiratory failure; d) in survivors, weaned from ECMO support, a progressive reduction in sPAP was detectable.

In our series, ICU mortality rate was 51%, a value comparable with previous investigations in ECMO COVID, despite wide ranges due to differences in number consistency, selection criteria and follow-up duration among previous reports [8, 10, 10] . Though the clinical characteristics (age, gender and comorbidities) of our population were comparable to previous investigations, our series comprises mainly COVID-related ARDS coming from peripheral centers and it is characterized by the co-existence of other organs' dysfunctions (as indicated by the incidence of renal replacement therapies).

In our opinion, the novelty of our investigation is represented by the fact that we performed systematic serial echocardiographic examinations in COVID-related ARDS on ECMO support.

While previous investigations [16, 20] performed echocardiographic assessment in these patients by means of only one exam, we made serial echocardiograms in each patient, presenting data at threetime points (before and after the start of the VV ECMO and just before death or discharge of the survivors. This may allow a more comprehensive view of RV changes before and during ECMO support.

Before ECMO support, a high incidence of RV dilatation and dysfunction was observed in our patients. Right ventricle alterations have been focused in several investigations mainly performed in mild-moderate COVID disease, documenting RV dilatation and dysfunction in about one third of patients, being associated with disease severity, progression and outcome [15, 16, 21] .

Several factors may account for RV abnormalities in COVID disease [13, [14] [15] [16] mainly including COVID-related alterations in lung parenchyma, in primis atelectasiae (responsible for increased RV afterload) and the effects of mechanical ventilation (increased intrathoracic pressures).

The effects of hypoxemia-induced increase in pulmonary arterial resistance are debated in COVID disease since the loss of pulmonary hypoxic vasconstriction in these patients. The incidence of RV dilatation and dysfunction was specifically assessed by echocardiography in COVID-related refractory ARDS requiring VV ECMO in a small series of patients [21] , in whom, in keeping with the results of the present investigation, RV alterations were reported in a high proportion of enrolled patients (63.3%). However, differently from our study, echocardiography was performed only once, in quite a limited number of patients, retrospectively analyzed at different time intervals since ECMO run, since echocardiographic exam was triggered by hemodynamic instability and/or refractory hypoxemia. In refractory ARDS from different etiologies than COVID on ECMO support, the reported incidence of RV dysfunction varies [22] from 18% (8/56) [23] to 32.6%, (30/92) [24] and 37% (13/35) [25] , so that a comparison with our results is quite difficult to be performed.

In our series, patients with RV dilatation and dysfunction showed a longer period of mechanical ventilation (protective ventilatory strategies in all patients), suggesting a relation between these two factors. Though a causality cannot be affirmed due to the small number of patients, our results are in keeping with the findings of a recent international multicenter registry of COVID-related ARDS patients treated with V-V ECMO [2] . Survival of patients treated with ECMO after longer periods of mechanical ventilation was lower than that of patients with early ECMO implantation. 7

However, no clear indication on the optimal duration of mechanical ventilation before ECMO implantation is so far available for COVID patients. While ELSO guidelines report that a period of more than 10 days of mechanical ventilation represents a contraindication for ECMO support [2] , a period of 7 days is reported as a cut-off by other papers [2, 4, 21] .

RV Dys was associated with increased values of transaminases, probably due to hepatic stasis and suggesting systemic venous congestion. However in RV Dys patients we failed to observe a higher incidence of renal replacement therapy, probably because of the high percentage of patients on renal support in the overall population, mostly before ECMO start. In non-survivors, all still on ECMO support, two different echocardiographic patterns may be identified, despite the limited number of patients. The first one is characterized by RV dysfunction and diastolic dysfunction (as inferred by higher values of E/e1): all these patients died for unfavourable progression of COVID pulmonary disease characterized by bilateral pulmonary

consolidations. The second one shows higher values of LVEF and normal RV dimensions and function: these patients died for septic shock.

In survivors, a progressive reduction in systolic pulmonary pressures was observed since ECMO removal to ICU discharge. This finding confirms the ability of echocardiographic examination to follow COVID pulmonary disease progression, in keeping with previous data of our group in patients with COVID-related ARDS [13] .

Among the possible etiologies of persistent RV alterations, the peculiar fibrotic and prothrombotic ARDS phenotype of COVID-19 vs ARDS from other etiologies (in primis H1N1) cannot be ruled out. In the review by Hariri et al [27] , it was reported pulmonary microthrombi as a peculiar feature of COVID-related ARDS. Although their incidence (57%) was similar to that observed in patients with SARS (58%), this is quite higher than that observed in ARDS from other etiologies, in primis H1N1 (24%).

The unique phenotype of COVID-related lung injury was confirmed by Margaroli et al [28] , who, by means of a spatial transcriptomic platform on autopsy-derived lung tissue, documented a more firboproliferative response of SARS-COV-2 infection versus H1N1. Overall, due to the distint fibrotic and prothrombotic ARDS phenotype of COVID-19, pulmonary vasculature is largely affected, being responsible for the increased RV afterload, and therefore possibly contributing to RV alterations especially in severe COVID-related ARDS.

We acknowledge some limitations. It is a single center investigation, enrolling a limited number of patients. However, ours is a high-volume ECMO center (even for critically-ill COVID patients) since we treated 35 COVID patients on ECMO support in a 11-month period, who were managed by the same intensive care team. In a recent multicenter trial [5], 190 COVID patients treated with ECMO were analysed, enrolled in 35 hospitals over a 5 month period (that is 5.4

patient/hospital in the study period). A similar small case valume at each center was observable also in an international multicenter registry [2, 4] . In both multicenter investigations, differences among centers in enrollment criteria and management cannot be ruled out. Another possible limitation is the lack of data on FAC and VTI, which were available only in a small percentage of patients, since they proved to be more sensitive for detecting RV dysfunction [16, 21] .

In patients on ECMO support for COVID-related ARDS, RV Dys is common, associated with longer mechanical ventilation and increased ICU mortality. RV Dys is detectable in nonsurvivors who died for unfavourable progression of COVID pulmonary disease, while survivors, weaned from ECMO support, showed a progressive reduction in pulmonary arterial pressures.

Overall our data underscore the clinical role of echocardiography in COVID-related ARDS supported by VV ECMO, since serial echocardiographic assessments (esplecially focused on RV changes) are able to reflect pulmonary COVID disease severity. Our data are to be confirmed by the systematic use of echocardiography in larger cohorts of COVID-related refractory ARDS on ECMO support. 

Extracorporeal life support for adults with acute respiratory distress syndrome

ECMO use in COVID-19: lessons from past respiratory virus outbreaks -a narrative review

Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai

Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers

Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients

Extracorporeal membrane oxygenation support in severe COVID-19

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Tatooles AJ Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

The Right Ventricle in COVID-19 Lung Injury: Proposed Mechanisms, Management, and Research Gaps JCVA

Echocardiographic assessment of the right ventricle in COVID -related acute respiratory syndrome

Cardiac involvment in COVID-19 -related Acute Respiratory Distress Syndrome

Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome

Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study

Right ventricular dysfunction in critically ill COVID-19 ARDS

Right ventricle dilation as a prognostic factor in refractory acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation

Harnessing nitric oxide for preventin, limiting and treating the severe pulmonary consequences of COVID-19

ECMO for ARDS due to COVID-19

Right Ventricular Dysfunction in Patients with Coronavirus Disease

The clinical role of echocardiography in severe COVIDrelated ARDS: Not just a technical tool

ECMO and Right Ventricular Failure: Review of the Literature

Right ventricular dysfunction and mortality after cannulation for venovenous extracorporeal membrane oxygenation

Right ventricular dysfunction and Pre Implantation Vasopressors in Refractory ARDS Supported by VV-ECMO

Assessment of right ventricular function with CT and echocardiography in patients with severe acute respiratory distress syndrome on extracorporeal membrane oxygenation

Timing of VV-ECMO therapy implementation influences prognosis of COVID-19 patients

Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review

Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies differential transcriptional signatures

CRP: C-Reactive Protein; LDH: lactose dehydrogenase; NT-pro BNP: N terminal pro Brain Natriuretic Peptide, IL-6: interleukin-6